The psoriasis (PsO) therapeutics market in Australia is dominated by biologics such as anti-TNF, anti-IL-17, anti-IL-23, and anti-IL-12/anti-IL-23 therapies. Among these, stiff competition exists among AbbVie’s Skyrizi, Novartis’ Cosentyx, Eli Lilly’s Taltz and Sun Pharma’s Ilumya. Against this backdrop, the pharma giants offer strong support to PsO patients in the branded space through digital channels, says GlobalData, a leading data and analytics company.
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of PsO in Australia is estimated to increase at an annual growth rate of 1.37% from 521,584 in 2021 to 561,567 in 2027.
In Australia, …
Related posts:
It’s raining tech unicorns in India with increasing digital adoption, says GlobalData
Netherlands on track to phase out coal power by 2030, says GlobalData
New low-cost start-up Bonza Airlines set to fill void in Australia’s domestic routes, says GlobalDat...
Reduced risk of CV morbidity and mortality demonstrated in FIGARO-DKD study
